Early clinical results of two tau tracers, [
Introduction
In spite of extensive knowledge about epidemiology, histopathological features, and genetics of Alzheimer disease (AD), only symptomatic treatment is available at this moment. 1 Therefore, there is a great need for an efficient treatment that can be initiated in an early phase of the disease. Definite diagnosis can still only be made postmortem on the basis of two pathological hallmarks: senile plaques (SP) and neurofibrillary tangles (NFTs). 2 Both SP and NFTs have been targeted by positron emission tomography (PET) ligands that can serve as diagnostic biomarkers, as this is a sensitive in vivo method to visualize and quantify AD-specific pathological changes in the living brain. 3 Much effort has been invested in the development of PET tracers that specifically bind to amyloid beta sheets (Ab). While a negative scan substantially limits the chance for development of AD and greatly influences clinic decision making, a positive amyloid PET scan is, by itself, not sufficient for a positive diagnosis for AD. 4 In contrast, even at late stages of AD, the burden of NFTs is closely related to the clinical symptoms of AD. [5] [6] [7] This likely implicates that a PET tracer that selectively targets tau aggregates could be a more relevant biomarker for AD conversion and for neurodegenerative tauopathies. 8 Several aspects make the development of tau imaging agents challenging. Through alternative splicing of the microtubule-associated protein tau gene, six isoforms of tau are expressed in the adult human central nervous system, giving rise to two sets of isoforms: those with three (3R) and those with four (4R) microtubule-binding domains, the latter one being more efficient in stabilizing microtubules. Normally, there is an equal ratio of both isoforms, but under pathological circumstances, several tauopathies express different isoform ratios with diverse morphologies. Due to these structural differences, it may be difficult to develop a tau-specific tracer, with similar affinity for every phenotype. 7 Furthermore, tau is subjected to many posttranslational modifications, which may result in conformational changes in the aggregates, potentially leading to different binding affinities of tau ligands. 9 Additionally, tau tracers need to be highly selective, as in AD, tau aggregates are coexistent with Ab deposits but occur in concentrations *5 to 20 times lower than Ab aggregates. 7 Despite many hurdles, several tau PET imaging agents have already been reported. 8, [10] [11] [12] [13] [14] 11 C]2-((1E, 3E)-4-(6-( 11 C-methylamino)pyridin-3-yl)buta-1,3-dienyl)benzo [d] thiazol-6-ol, evaluation in humans has been reported. 15, 16 [ 18 F]FDDNP, the oldest PET tracer in this series, was first identified as having affinity for Ab and NFTs. High retention was found in brain of patients with AD and in other tauopathies, but its low Ab/tau selectivity, relatively low affinity for tau, and small dynamic range of signal limit its use as tau PET tracer. 16 ,17 [ 
F]T808 and [
18 F]T807 showed reasonable affinity (K D , respectively 22 and 15 nmol/L) and specificity values (respectively 27-and 25-fold higher binding affinity for NFTs over Ab) in autoradiography K D -determination studies on human AD brain tissue sections. 8, 11 Early clinical evaluation of both imaging agents seems to confirm preclinical findings. 18, 19 With favorable pharmacokinetics and a binding pattern consistent with the Braak staging, they are currently among the most promising PET candidates for tau imaging. 15, 20 Substantial defluorination has however been observed with [ 18 F]T808, and no full kinetic modeling of the tracers has been reported yet. 16, 19 Comparable in vitro binding assay studies have been performed by other groups with radiolabeled arylquinoline derivatives THK-523, THK-5105, and THK-5117 and recently also with THK-5351. 16 Although [ 18 F]THK-523 showed high affinity and specificity for tau fibrils in vitro, 15 unfavorable pharmacokinetics and high white matter binding pushed the development of the new 2-arylquinoline derivatives [ 18 
F]THK-5105 and [
18 F]THK-5117, with higher affinity and lower white matter binding. 13, 20 Compared to these five fluorine-18-labeled compounds, the carbon 11-labeled compound PBB3 is so far the only one published showing high affinity for tau in AD as well as non-AD tauopathies, implying that it may detect multiple tau isoforms. 15 However, the tracer shows rapid metabolism and a challenging radiosynthesis because of its sensitivity to photoisomerization.
In order to obtain comparative preclinical data for [ 18 F]T808 and [
18 F]T807, we have performed biodistribution, radiometabolite, and autoradiography studies, properties that determine the potential of new PET tracers, as no (comparable) data of these experiments are available in the literature. These properties were also compared for a number of other existing tau tracers and newly designed radioligands in semiquantitative autoradiography studies and competition binding assays, since the aim of this research was to identify structural moieties needed for selective interaction with NFTs and to provide a straightforward comparison of the currently reported tau tracers.
Materials and Methods

General
The precursor and authentic reference material for [ 18 21, 22 All other chemicals and reagents were purchased from commercial sources and used without further purification. The TLC plates (Macherey-Nagel, Düren, Germany) were developed using mixtures of ethyl acetate and heptane or dichloromethane and methanol as mobile phase. Automated flash column chromatography was performed using silica cartridges (GraceResolv 12 g, Grace, Deerfield, Illinois) on a Reveleris X2 flash system (Grace) equipped with an evaporative light-scattering detector and ultraviolet (UV) detector at 254 nm. 1 H nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance II spectrometer (400 MHz, 5 mm probe; Fällanden, Switzerland) using deuterated methanol (MeOD-d4) or deuterated dimethyl sulfoxide (DMSO-d6) as indicated. Chemical shifts are reported in parts per million downfield from tetramethylsilane (d ¼ 0). Coupling constants are reported in hertz (Hz). Splitting patterns are defined by s (singlet), d (doublet), dd (double doublet), dt (double triplet), t (triplet), q (quartet), or m (multiplet). Exact mass measurements were performed on an ultra-high resolution time-offlight mass spectrometer (maXis impact LC/MS, Bruker, Bremen, Germany) equipped with an orthogonal electrospray ionization (ESI) interface. Acquisition and processing of data were conducted using HyStar and Compass DataAnalysis (version 3.2; Bruker), respectively. Calculated monoisotopic mass values were obtained using MarvinSketch (version 6.1.0; ChemAxon http://www.chemaxon.com). High-performance liquid chromatography (HPLC) analysis was performed on a LaChrom Elite HPLC system (Hitachi, Darmstadt, Germany) connected to a UV detector set at 254 nm. For analysis of radiolabeled compounds, the HPLC eluate, after passing through the UV detector, was led over a 3-inch sodium iodide activated with thallium NaI(Tl) scintillation detector connected to a single-channel analyzer (GABI box; Raytest, Straubenhardt, Germany). Data were acquired and analyzed using GINA Star (Raytest) data acquisition systems. Quantification of radioactivity in samples of biodistribution and radiometabolite studies was performed using an automated g-counter equipped with a 3-inch NaI(Tl) well crystal coupled to a multichannel analyzer, mounted in a sample changer (Wallac 2480 Wizard 3q; Wallac, Turku, Finland). The values are corrected for background radiation, physical decay, and counter dead time. Alzheimer disease slices of 10 mm thick from the visual cortex of a 68-year-old woman in the latest Braak stage (V-VI) were provided by University Hospitals Leuven (Neurology Department, Leuven, Belgium) after approval from the local ethics committee. Animals were housed in individually ventilated cages in a thermoregulated (*22 C), humiditycontrolled facility under a 12-hour-12-hour light-dark cycle, with access to food and water ad libitum. All animal experiments were conducted according to the Belgian code of practice for the care and the use of animals, after approval from the university animal ethics committee.
Chemistry 2-(4-Nitrophenyl)benzo[d]thiazole (TAU1).
Compound was synthesized according to a described procedure. 23 Liquid chromatography-high resolution mass spectrometry (LC-HRMS) (ESI) calculated for C 13 2-Methoxy-5-f5H-pyrido [4,3-b] indol-7-ylgpyridine (TAU6). The compound was synthesized according to T807's patent application 21 using 3-bromo-4-nitropyridine and 4-bromophenylboronic acid as starting materials in the first step and 2-methoxypyridine-5-boronic acid for the second step ( Figure 1 7-(4-Methoxyphenyl)-5H-pyrido [4,3-b] indole (TAU7). The compound was synthesized according to T807's patent application 21 using 3-bromo-4-nitropyridine and 4-bromophenylboronic acid as starting material in the first step and 4-methoxyphenylboronic acid for the second step ( Figure 1 Methyl 5-f5H-pyrido [4,3-b] indol-7-ylgpyridine-2-carboxylate (TAU8). The ompound was synthesized according to T807's patent application 21 using 3-bromo-4-nitropyridine and 4-bromophenylboronic acid as starting materials in the first step and 4-methoxycarbonylphenylboronic acid for the second step ( Figure 1 7-(6-chloropyridin-3-yl)-5H-pyrido [4,3-b] indole (precursor for T807).
Step 1: A mixture of 3-(4-bromophenyl)-4-nitro-pyridine 21 (0.70 g, 2.51 mmol), (4-chloro-3-pyridyl) boronic acid (0.592 g, 3.76 mmol), and potassium carbonate (0.693 g, 5.02 mmol) in 1,4-dioxane (14 mL) and water C, 16 h, iii ¼ P(OEt) 3 , 100 C, 3 h, iv ¼ phosphorus pentoxide/methanesulfonic acid (PPMA), 100 C, 1 h.
(14 mL) was degassed under N 2 flow for 10 minutes. Then, tetrakis(triphenylphosphine)palladium 0 (0.145 g, 0.125 mmol) was added and the mixture was heated at 140 C for 10 minutes under microwave irradiation. The reaction mixture was diluted with dichloromethane and washed with water. The organic layer was separated, dried (MgSO 4 ), filtered, and the solvent was removed in vacuo. The residue was purified by flash chromatography (silicagel: ethyl acetate in heptane 0/ 100 to 40/60). The desired fractions were collected and the solvents removed in vacuo to give 2-chloro-5-[4-(4-nitro-3-pyridyl)phenyl]pyridine (0.34 g, 43% yield) as a pale yellow solid that was used as such for the next reaction step.
Step 2: A solution of 2-chloro-5-[4-(4-nitro-3-pyridyl)-phenyl]pyridine (0.30 g, 0.96 mmol) in triethyl phosphite (3 mL, 17.5 mmol) was heated at 100 C for 3 hours in a sealed tube. After this time, the mixture was cooled to 0 C and the precipitate filtered off and washed with cold diethyl ether. The solid was purified by flash chromatography (silicagel: MeOH/NH 3 in dichloromethane 0/100 to 04/96). The desired fractions were collected, the solvents were removed in vacuo, and the residue was triturated with diethyl ether to yield 7- 
-a]benzimidazole (1.00 mg, 2.65 mmol) was dissolved with N,N-Diisopropylethylamine DIPEA (2 mL, 11.47 mmol) in methanol MeOH (0.25 mL, 6.18 mmol). Palladium (1.00 mg, 0.94 mmol) was added, and the mixture was degassed thoroughly three times and placed under tritium atmosphere and allowed to reach room temperature while stirring for 30 minutes. Next, the tritium gas was diverted to a waste trap, and volatiles were lyophilized to a waste vial. The reaction product was quenched three times with 150 mL MeOH to remove labile tritium atoms, and the solvent was lyophilized to a waste vial. Then, the reaction product was filtered over an acrodisc (Pall 1-mm syringe filter) and dissolved in 10 mL EtOH. Ten mL of the final product was diluted in 10 mL MeOH of which 10 mL was counted in 3 mL liquid scintillation counter LSC (253.4 MBq/mL). The crude mixture was purified using RP-HPLC.
pheny]-N-methylamine (0.42 mg, 1.17 mmol) was dissolved in dichloromethane DCM with [(cod)Ir(Py)(PCy3)]PF6 (0.78 mg, 0.97 mmol). The mixture was thoroughly degassed in liquid N 2 and placed under 150 mbar tritium for 1 hour at room temperature, reaching 838 mbar. The diluted gas was trapped on the waste bed, and the solvent waste was lyophilized to the waste vial and rinsed via lyophilization three times with MeOH. Afterward, the residue was dissolved in 10 mL EtOH. Ten mL of the latter solution was diluted in 10 mL MeOH, of which 10 mL was counted in 3 mL LSC (534.6 MBq/mL). The crude mixture was purified using RP-HPLC.
Biodistribution Studies
Biodistribution of [ 18 F]T808 and [ 18 F]T807 was studied in healthy male Naval Medical Research Institute (NMRI) mice (body weight: 30-40 g) at 2, 10, 30, and 60 minutes postinjection (PI; n ¼ 4/time point). Mice were anesthetized (2.5% isoflurane in O 2 at 1 L/min flow rate) and injected with about 0.9 MBq of the tracer via a tail vein and killed by decapitation at above-specified time points. Blood and major organs were collected in tared tubes and weighed. Radioactivity in blood, organs, and other body parts was counted using an automated g-counter. For the calculation of total radioactivity in blood, bone, and muscle, masses were assumed to be, respectively, 7%, 12%, and 40% of the total body mass.
Radiometabolites
Plasma radiometabolites. The NMRI mice were anesthetized with isoflurane (2.5% in O 2 at 1 L/min flow rate) and injected with [ 18 F]T808 or [ 18 F]T807 (*3.7 MBq) via a lateral tail vein. They were killed by decapitation at 2, 10, 30, or 60 minutes PI (n ¼ 3/time point). Blood was collected in EDTA-containing tubes (4 mL tubes; BD vacutainer, BD, Franklin Lakes, New Jersey) and stored on ice. Blood was subsequently centrifuged at 2330 Âg for 10 minutes to separate the plasma. Plasma (0.5 mL) was isolated and spiked with 10 mg of authentic T808 or T807 and analyzed by HPLC (Chromolith C 18 , 3.0 Â 100 mm; Merck, Darmstadt, Germany) and eluted with gradient mixtures of 0.05 mol/L NaOAc pH 5.5 (A) and CH 3 CN (B; 0-4 minutes: isocratic 0% B, 0.5 mL/min; 4-14 minutes: linear gradient 0% B to 90% B, 1 mL/min; 14-17 minutes: isocratic 90% B, 1 mL/min). After passing through a UV detector at 254 nm coupled in series with a 3-in NaI(Tl) scintillation detector and connected to a singlechannel analyzer, the HPLC eluate was collected as 1 mL fractions (model 2110 fraction collector; Biorad, Hercules, California). The radioactivity of fractions was counted in an automated g-counter.
Perfused brain radiometabolites. For each time point, three NMRI mice were injected with [
18 F]T808 or [ 18 F]T807 (*7.4 MBq). At 10 or 60 minutes PI, the mice were killed by an overdose of pentobarbital (Nembutal; CEVA Santé Animale, Brussels, Belgium; 150 mg/kg intraperitoneally) and perfused with saline via the left ventricle. Brain was isolated and homogenized in CH 3 CN (2 mL). After centrifugation at 3000 rpm (1310Â g) for 5 minutes, the supernatant (*1 mL) was collected, diluted with H 2 O (1 mL), and filtered through a 0.22-mm filter (Millipore, Bedford, Massachusetts). About 0.5 mL of the filtrate was further diluted with an equal volume of H 2 O and spiked with 20 mg authentic T808 or T807 before being analyzed on an analytical XBridge column (C 18 Immunohistochemistry Human brain slices. Frozen sections were stained using Dako automated stainer (DakoCytomation, Glostrup, Denmark), using antisera generated against Ab (M0872-clone 6F/3D; DakoCytomation, Glostrup, Denmark; 1:100 dilution) and Tau (T6402; Sigma Aldrich, St Lous, Missouri; 1:250 dilution), according to the manufacturer's protocol. Mouse brain slices. Transgenic mice expressing mutant human P301L tau were killed by decapitation, brains were removed from the skull, snap frozen in 2-methylbutane (À30 C), and stored at À20 C until 20-mm thick sections were sliced for immunohistochemistry. Sections were dried, fixed in formalin, and incubated with hydrogen peroxide (Vector labs, Burlingame, California; S2023) for 5 minutes and blocking reagent during 1 hour (mouse-on-mouse [MOM] kit; Vector labs; BMK-2202). Anti-AT8 antibody (in-house, 0.2 mg/mL in MOM diluent) was applied to the sections overnight. Next day, the slices were incubated with horseradish peroxidaseconjugated antimouse secondary antibody (Envision; DAKO, Glostrup, Denmark; K4000), followed by chromogenic diamino benzene labeling (DAKO, K3468). After counterstaining with hematoxylin, sections were dehydrated and mounted with organic mounting medium (Vectamount, Vector labs; H-5000).
In Vitro Autoradiography Binding Inhibition Studies
Air-dried, frozen, 10-mm thick slices of the visual cortex of an patient with AD (68-year old female with Braak stage V-VI) were incubated for 60 minutes with [
18 F]T808 or [ 18 F]T807 (0.74 MBq/500 mL per section) and subsequently washed with mixtures of phosphate-buffered saline (PBS) and ethanol as described elsewhere. 11 In the case of [ 11 C]PiB, slices were incubated with 0.37 MBq/500 mL per section for 10 minutes. To assess specificity of binding, slices were incubated with tracer in the presence of 1 mmol/L of authentic T808, T807, astemizole, lansoprazole, THK-5105, BF-158, BF-170, TAU1-8, or PiB. After drying, the slices were exposed to a phosphor storage screen (super-resolution screen; Perkin Elmer, Waltham, Massachusetts). Screens were read in a Cyclone Plus system (Perkin Elmer) and analyzed using Optiquant software (Perkin Elmer 
PHF Tau and Amyloid Plaques Isolation From Human AD Brain
Enriched paired helical filaments PHF tau fractions were prepared according to a slightly modified version of the protocol described by Greenberg and Davies 28 using human AD brain tissue (occipital cortex with high tau fibril load). Briefly, frozen human AD brain samples (*10 g) were homogenized with 10 volumes of cold homogenization buffer (10 mmol/L Tris, 800 mmol/L NaCl, 1 mmol/L ethylene glycol tetraacetic acid EGTA, 10% sucrose, pH 7.4) containing PhosSTOP phosphatase and cOmplete EDTA-free protease inhibitor (Roche, Vilvoorde, Belgium) on ice. After centrifugation at 27.000 Â g for 20 minutes at 4 C, the supernatant was recovered and 1% (w/v) N-lauroylsarcosine and 1% (v/v) 2-mercaptoethanol were added. The N-lauroylsarcosine/2-mercaptoethanol supernatant was incubated for 2 hours at 37 C while shaking on an orbital shaker. Subsequently, ultracentrifugation at 108.000 Â g for 1.5 hours at room temperature enriched PHF tau in the pellet. Supernatant was removed, and the pellet was carefully rinsed twice with a small volume of Tris-buffered saline (TBS; 50 mmol/L Tris, 150 mmol/L NaCl, pH 7.4). Finally, the PHF tau pellet was recovered in TBS and resuspended to ensure sample homogeneity. Small aliquots were stored at À80 C. Frozen human AD brain samples (10 g-occipital cortex with high amyloid plaques load) were homogenized with a 7-fold volume of cold homogenization buffer (250 mmol/L sucrose, 20 mmol/L Tris base, 1 mmol/L EDTA, 1 mmol/L EGTA, and PhosSTOP phosphatase and cOmplete EDTAfree protease inhibitor) on ice. After centrifugation at 27.000 Â g for 20 minutes at 4 C, cell debris was removed. Supernatant containing amyloid plaques was aliquoted and stored at À80 C.
In Vitro Competitive Radioligand Binding Assays
The competitive radioligand binding assays measure the binding of a radiolabeled reference ligand in the presence of a dose-response concentration range of test compounds T807, T808, lansoprazole, astemizole, PiB, THK5105, TAU1, and TAU4-8 (TAU2-3 were not evaluated due to solubility problems). Briefly, PHF tau preparations were diluted to 100 mg protein/mL in PBS buffer with 5% ethanol. In a 96-well format, 3 H-T808 (specific activity 1 GBq/mmol) was added at a final concentration of 10 nmol/L to increasing amounts of test compound in the presence of 20 mg protein of PHF tau preparation. Nonspecific binding was defined as the number of counts remaining in the presence of 50 mmol/L thioflavin T (common beta sheet binder). After 2 hours incubation at room temperature, the unbound ligand was removed by filtration of the binding mixtures over GF/B glass filters using a Filtermate 96 harvester instrument (Perkin Elmer, Zaventem, Belgium). The filters were washed three times with PBS buffer containing 20% ethanol. After overnight drying of the filter plate, Microscint O liquid (Perkin Elmer) was added, and the amount of radiolabeled ligand bound to the fibrils was measured by liquid scintillation counting in a Topcount instrument (Packard Instrument, Meriden, Connecticut).
Values for half-maximal inhibitory concentration (IC 50 ) were determined from displacement curves of at least two independent experiments using GraphPad Prism software (GraphPad Software, San Diego, California).
To determine compound binding to the amyloid plaques, a similar assay was put in place but with some minor modifications. Briefly, amyloid preparations were diluted to 150 mg protein/mL in 50 mmol/L Tris with 0.1% bovine serum albumin (BSA) and 5% ethanol.
3 H-AV-45 (florbetapir-specific activity 2 GBq/mmol) was added at a final concentration of 10 nmol/L to increasing amounts of test compound in the presence of 30 mg protein of amyloid plaques preparation. Nonspecific binding was determined in the presence of 500 mmol/L thioflavin T. After 150 minutes incubation at room temperature, the binding mixtures were filtered over GF/B glass filters. The filters were washed three times with PBS buffer containing 20% ethanol. Subsequent steps were identical to those described for the PHF tau preps. . Purification of the crude radiolabeling reaction mixture was done on an isocratic RP-HPLC system using a mixture of acetate buffer and ethanol as mobile phase. Radiochemical purity was examined using HPLC on an analytical C 18 column and was more than 99%. Both tracers were obtained within a total synthesis time of 60 minutes and were collected with an average specific radioactivity of 119 GBq/ mmol at the end of synthesis (EOS, n ¼ 7) for [ Table 2 ). The detected radiometabolites were more polar than the intact tracers, and no radiometabolites more lipophilic than the intact tracer were detected 60 minutes PI. The recovery of the HPLC columninjected radioactivity for [ 18 
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F]T808 and [
18 F]T807 was 85% and 70%, respectively (n ¼ 6).
In vitro Autoradiography Binding Studies
Digital autoradiography with [ 18 F]T808 and [ 18 F]T807 on human AD slices showed binding to tau-rich regions in the 1 to 3 cortical layers and 5 to 6 cortical layers of the visual cortex (Figure 4) . Immunohistochemistry with tau and Ab antibodies, performed on adjacent slices, identified numerous NFTs and neuritic plaque deposits, confirming colocalization of tracer binding with NFTs ( Figure 5 ). To assess the specificity of the tracer binding to these NFTs, blocking studies with several tau-specific ligands and Ab-specific ligands were performed. An overview of the different compounds used to block (at 1 mmol/L concentration) the binding of [ 18 (Figure 6 ). 
In vitro Competitive Radioligand Binding Assays
Discussion
One of the aims of this study was to determine some important preclinical properties of [ 18 F]T808 and [ 18 F]T807, such as brain uptake, washout from brain, and formation of radiometabolites, since these ligands are among the most selective tau tracers with high affinity for NFTs reported in literature to date. 15 In addition, with a clogD 7.4 between 2.0 and 3.5, a polar surface area <80 Å 2 , and a low molecular mass (<500 Da), both compounds show optimal molecular features for a passive transfer across the blood-brain barrier (BBB). 29 Although these tracers have already been evaluated in clinical trials, 18, 19 preclinical data remain essential in the search for new and better 18 19 These results were expected based on the m-PET biodistribution data from the original report on [ 18 F]T808. 8 The mPET data suffer however from limited resolution when compared to an in vivo biodistribution study in which the radioactivity of individual organs is counted after dissection, and thus results of the two approaches are only partly comparable. 19 In brain, ideally no radiometabolites should be present, since they may have different brain kinetics and brain distribution than the parent compound and thus complicate tracer modeling and PET quantification. In their original article on preclinical properties of [ 18 F]T808, Zhang et al mention the absence of radiometabolites in mouse brain. 8 Metabolic stability was however conducted in liver microsomal assays of mice and humans, where rapid metabolism was shown (in the presence of cofactor NADPH) 60 minutes after incubation. Furthermore, while polar metabolites might not always cross the BBB, ex vivo brain metabolite studies should confirm this. We therefore performed ex vivo brain metabolite studies in mice, which showed the presence of two unidentified polar radiometabolites the fraction of which is 66% at 60 minutes PI (see Table 2 ). Further, in vitro brain radiometabolite analysis is required to determine whether metabolism is peripheral with subsequent passage of the radiometabolite through the BBB and/or whether it occurs within the brain.
In the second part of this study, we performed a semiquantitative autoradiography screening with [
18 F]T808 and [ 18 F]T807 as reference tracers, in combination with several tau-specific ligands reported in the literature (group 1 in Table  3 ) and with newly synthesized ligands containing structural moieties with known affinity for tau, such as benzothiazoles, carbazoles, and phenylthiazolylhydrazide compounds (group 2 in Table 3 ). Similar autoradiography studies were also performed with [ 11 C]PiB to examine the selectivity of several compounds for Ab (group 3 in Table 3 (Table 4) . These binding studies provide additional, quantitative information on the affinity of several cold compounds for purified human tau and Ab, but the absence of off-target binding should also be taken into account when comparing the results of autoradiography blocking studies on AD slices. Overall, the screening assays provide valuable information on the nature of structural moieties necessary for binding to tau fibrils and thus can be very helpful in the development of new specific high-affinity ligands for tau. 8, 11 The disadvantage of using a particular radioligand in the autoradiography studies, [ 18 F]T808 in our case, to screen for new compounds with high affinity for tau is that allosteric binding is overlooked, and only compounds that bind to identical regions of tau are detected. An alternative approach to screen for new tau selective compounds could be the use of fluorescent dyes such as thioflavin or congo red derivatives. Such compounds emit a stronger fluorescent signal when interacting with beta-sheet aggregates, making quantification challenging. Furthermore, these derivatives show affinity for many different misfolded proteins with beta-sheet structures and are therefore less specific to screen for tau ligands. Thus, using the highly selective and specific tau tracer [ 18 F]T807, displaced by T808, showed however some variability (see Table 3 ). Self-block, on the other hand, was comparable for both compounds (group 1 in Table 3 ). Competition blocking studies showed however higher pIC 50 values of T808 than T807 for purified tau but higher specificity of T808 compared to T807. These results are in disagreement with the published affinity values of T807 and T808. Be that as it may, Kd affinity values were determined on human AD slices in the literature, while in our competition blocking studies, purified human tau was used. 8, 11 Both tracers may, however, be considered as benchmark compounds for tau, as they have high affinity and selectivity for tau fibrils. In the case of AD in which the concentration of tau aggregates in the human brain can be 5 to 20 times lower than that of Ab aggregates, 7 high affinity combined with a high selectivity for tau is a prerequisite for a good tau PET imaging agent.
In the first group of reference ligands for the semiquantitative autoradiography experiments, authors of the Tohoku university described three tau imaging agents, among others 10,13 : TAU1  <5  >3998  <5  >4398  TAU4  <5  >3998  <5  >4398  TAU5  <5  >3998  <5  >4398  TAU6  <5  >3998  <5  >4398  TAU7 7 13 The introduction of an extra methyl group on the structure of BF-170, compared to the structure of BF-158 (Figure 7 ), seems to lower the binding affinity for tau (respectively 84% inhibition instead of 93%) in our autoradiography assay. THK5105 was also evaluated in the competition binding assays, where it showed high affinity for tau (pIC 50 of 7.07), but also for Ab (pIC 50 of 7.27), thus resulting in low selectivity. The latter results are at odds with the reported specificity of THK-5105 (25-fold specificity for tau over Ab) 13 but could partially be explained by a different screening approach, as affinity was originally determined on recombinant Ab 1-42 and the K18DK280-tau construct. 13 On the other hand, the benzimidazole compounds astemizole and lansoprazole were able to decrease binding of [ 18 F]T808 only up to 22% (see Table 3 ), although both imaging agents showed affinity for heparin-induced tau polymers and isolated preparations of human PHFs. [32] [33] [34] The lack of binding inhibition by both benzimidazole structures, both in autoradiography studies and in the competition binding assays, may be due to either the difference in human PHFs across the assays or the allosteric binding of astemizole and lansoprazole, compared to T808. 17 While the arylquinoline and the benzimidazole imaging agents described earlier were only recently evaluated in vitro as selective tracers for tau fibrils, [ 11 C]PiB was among the first PET imaging agents developed to visualize AD pathology in the living brain. 35, 36 PiB preferentially binds to senile plaques (SP). 36 As expected, PiB showed little or no inhibition of [ 18 F]T808 binding (see Table 3 ), confirming the fact that the binding properties of T807 and T808 are different from those of Ab PET-imaging agents with benzothiazole scaffolds. This was confirmed by our autoradiography blocking studies in which negligible inhibition of the binding of [ 11 C]PiB was observed for T807 (11%) and T808 (17%), suggesting that these agents are relatively selective for tau versus Ab. The latter result was also shown for T808 in the competition binding assays (Table 4) .
In the second group, newly synthesized ligands were included containing scaffolds with presumed affinity for tau fibrils 8, 11, 37, 38 such as benzothiazoles (TAU1-3), carbazoles (TAU6-8), and phenylthiazolylhydrazides (TAU4-5). Five of eight compounds tested (TAU1 and TAU5-8) were able to inhibit the binding of [
18 F]T808 with more than 50%, three of which even displaced it more than 90%. The efficacy of the latter three compounds (TAU6-8) was expected, as they are structurally related to T807 and T808. The high potency of TAU6-8 proves that the pyridine moiety of T807 allows diverse substitution without compromising its affinity for PHFs. The absence of displacement of [ 11 C]PiB binding by these three compounds suggests that they also selectively bind to tau (see Table 3 ). A distinct difference was observed between TAU4 and TAU5. The latter differs from TAU4 by the presence of a pyridine ring instead of a phenyl ring, resulting in an extra 26% inhibition (see Table 3 ). A side chain with a pyridine ring thus might be beneficial to interact with NFTs at similar sites as T807 and T808. The ligands TAU1-3 and PiB share a similar phenylbenzothiazole core structure, but only TAU1 inhibited [ 18 F]T808 binding to an extent of 75% (see Table 3 ). In the competition binding assay, only TAU7 showed affinity for tau and Ab (with a pIC 50 of 7.07 and 7.27, respectively). Discrepancy between the autoradiography blocking studies and the competition binding assays could however, as previously mentioned, be explained by the fact that in the competition assays purified tau and Ab has been used, while in the autoradiography studies both aggregated proteins are in their ''natural'' environment, as brain slices of the latest Braak stage were used.
[ 18 F]T808 was additionally evaluated in tau overexpressing transgenic mice (P301L model). We did not observe any specific binding, in contrast to the experiments using human brain slices. This may be explained by several contributing factors: differences in posttranslational modifications between mice and humans, different composition of tau-isoforms (mice only express 4R isoforms of tau, whereas 3R and 4R are equally expressed in [AD] humans). and ultrastructural differences in cross-beta sheets. 39 Similar mPET results were observed by Xia et al in the P301L transgenic mice model. 11 Nonetheless, several tau tracers (THK-523, N-methyl lansoprazole, and PBB3) were reported to bind to tau in transgenic mice models in autoradiography ARX-and mPET studies. 10, 12, 14 Thus, the difference in binding affinity of T808 between murine and human tau could also be explained by the fact that NFTs and SPs are subject to an aging process throughout the disease so that the structure of relatively young plaques in mouse models may be quite different from that of the older NFTs and SPs in patients with AD. 35 Hence, tau tracers may show affinity for specific subfractions of human aggregated tau, as it is the case for [ 11 C]PBB3, which is able to bind to different tau fractions (3R and/or 4R), namely, tau present not only in AD but also in other tauopathies, 14 properties which make the development of a more stable and 18 F-labeled compound worth pursuing.
Conclusion
By performing parallel biodistribution, metabolite, and autoradiography studies with 18 F]T808 to murine tau in the P301L transgenic mouse model was observed. Differences in affinity between human and murine tau might be explained by interspecies differences between tau fibrils but is more likely due to existence of specific subfractions of human aggregated tau, compared to murine tau. Currently, reasonably good tau markers for AD have been developed in terms of affinity, biodistribution, and selectivity, but development of novel ligands that can target tau aggregates more selectively in different tauopathies, with little or no interaction with Ab, and that are also able to bind to different tauopathies and transgenic mice models are required.
